We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+9.57%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$190M
AUM Growth
+$18.1M
Cap. Flow
+$4.61M
Cap. Flow %
2.42%
Top 10 Hldgs %
89.79%
Holding
38
New
5
Increased
4
Reduced
5
Closed
–

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$3.14M
2
AEGR
Aegerion Pharmaceuticals
AEGR
+$1.17M
3
XNCR icon
Xencor
XNCR
+$789K
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$563K
5
CERS icon
Cerus
CERS
+$425K

Top Sells

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$1.1M
2
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$481K
3
QTNT
Quotient Limited Ordinary Shares
QTNT
+$340K
4
ARAY icon
Accuray
ARAY
+$183K
5
PTCT icon
PTC Therapeutics
PTCT
+$183K

Sector Composition

Rank Sector Weight
1 Healthcare 86.14%
2 Consumer Staples 4.01%
3 Energy 3.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$96.9M 50.88%
840,163
+26,252
+3% +$3.14M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$46.5M 24.44%
206,756
+200
+0.1% +$41.8K
YTEN
3
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$7.63M 4.01%
221
– –
VRML
4
DELISTED
Vermillion, Inc.
VRML
$4.69M 2.46%
2,717,514
– –
EQT icon
5
EQT Corp
EQT
$31B
$3.42M 1.8%
75,868
– –
MDVN
6
DELISTED
MEDIVATION, INC.
MDVN
$2.8M 1.47%
43,360
– –
HNSN
7
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$2.54M 1.34%
292,093
– –
BIOL
8
DELISTED
Biolase, Inc.
BIOL
$2.4M 1.26%
95
– –
SWN
9
DELISTED
Southwestern Energy Company
SWN
$2.24M 1.18%
96,483
– –
GILD icon
10
Gilead Sciences
GILD
$167B
$1.83M 0.96%
18,670
– –
CLR
11
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$1.43M 0.75%
32,674
– –
MASI
12
DELISTED
Masimo
MASI
$1.21M 0.63%
36,600
– –
AEGR
13
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.2M 0.63%
+46,000
New +$1.17M
OMED
14
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$1.15M 0.61%
44,689
+22,200
+99% +$563K
ARAY icon
15
Accuray
ARAY
$30.8M
$1.12M 0.59%
120,300
-23,000
-16% -$183K
QDEL icon
16
QuidelOrtho
QDEL
$1.19B
$1.05M 0.55%
38,975
– –
TTHI
17
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$1.03M 0.54%
150,746
– –
PTCT icon
18
PTC Therapeutics
PTCT
$6.52B
$1.03M 0.54%
16,900
-3,000
-15% -$183K
ASPX
19
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$902K 0.47%
9,000
-16,500
-65% -$1.1M
MRK icon
20
Merck
MRK
$315B
$862K 0.45%
15,720
– –
TRNX
21
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$787K 0.41%
30,000
-19,000
-39% -$481K
OVV icon
22
Ovintiv
OVV
$16.2B
$777K 0.41%
13,940
– –
XNCR icon
23
Xencor
XNCR
$1.3B
$766K 0.4%
+50,000
New +$789K
CELGZ
24
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$634K 0.33%
213,432
– –
CTRA
25
DELISTED
Coterra Energy
CTRA
$620K 0.33%
21,000
– –
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2015 Portfolio in Review

As of Q1 2015, Birchview Capital held 38 positions worth $190M, up 11% from $172M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Birchview Capital's Q1 2015 filing shows 5 new, 4 increased and 5 reduced positions. Its largest new stake was Aegerion Pharmaceuticals: 46,000 shares worth $1.2M. The largest sale was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $1.1M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Consumer Staples and Energy.

  • Birchview Capital's largest Q1 2015 buy was Aegerion Pharmaceuticals: 46,000 shares worth $1.2M.
  • Birchview Capital added most to Celgene Corp in Q1 2015, an estimated $3.14M increase.
  • Birchview Capital's biggest Q1 2015 reduction was AUSPEX PHARMACEUTICALS INC COM STK (DE), cutting an estimated $1.1M.
  • Birchview Capital's ten largest holdings make up 90% of its $190M portfolio in Q1 2015.
  • Birchview Capital opened 5 new positions and closed 0 in Q1 2015.
  • Birchview Capital's portfolio value rose 11% quarter-over-quarter to $190M.

Based on Birchview Capital's 13F filing for Q1 2015, filed 24 Apr 2015.